Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin

被引:149
|
作者
Bartolucci, Alfred A. [1 ]
Tendera, Michal [2 ]
Howard, George [1 ]
机构
[1] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA
[2] Med Univ Silesia, Div Cardiol 3, Katowice, Poland
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 107卷 / 12期
关键词
RANDOMIZED CONTROLLED-TRIAL; PUBLICATION BIAS; GRAPHICAL TEST; DISEASE;
D O I
10.1016/j.amjcard.2011.02.325
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several meta-analyses have focused on determination of the effectiveness of aspirin (acetylsalicylic acid) in primary prevention of cardiovascular (CV) events. Despite these data, the role of aspirin in primary prevention continues to be investigated. Nine randomized trials have evaluated the benefits of aspirin for the primary prevention of CV events: the British Doctors' Trial (BMD), the Physicians' Health Study (PHS), the Thrombosis Prevention Trial (TPT), the Hypertension Optimal Treatment (HOT) study, the Primary Prevention Project (PPP), the Women's Health Study (WHS), the Aspirin for Asymptomatic Atherosclerosis Trial (AAAT), the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial, and the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial. The combined sample consists of about 90,000 subjects divided approximately evenly between those taking aspirin and subjects not taking aspirin or taking placebo. A meta-analysis of these 9 trials assessed 6 CV end points: total coronary heart disease, nonfatal myocardial infarction (MI), total CV events, stroke, CV mortality, and all-cause mortality. No covariate adjustment was performed, and appropriate tests for treatment effect, heterogeneity, and study size bias were applied. The meta-analysis suggested superiority of aspirin for total CV events and nonfatal MI, (p <0.05 for each), with nonsignificant results for decreased risk for stroke, CV mortality, and all-cause mortality. There was no evidence of a statistical bias (p >0.05). In conclusion, aspirin decreased the risk for CV events and nonfatal MI in this large sample. Thus, primary prevention with aspirin decreased the risk for total CV events and nonfatal MI, but there were no significant differences in the incidences of stroke, CV mortality, all-cause mortality and total coronary heart disease. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1796-1801)
引用
收藏
页码:1796 / 1801
页数:6
相关论文
共 50 条
  • [21] Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease
    Raju, Nina
    Sobieraj-Teague, Magdalena
    Bosch, Jackie
    Eikelboom, John W.
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (05): : E35 - E36
  • [22] CARDIOVASCULAR EFFICACY AND BLEEDING RISK OF ASPIRIN IN PRIMARY PREVENTION POPULATIONS: A META-ANALYSIS OF RANDOMIZED TRIALS
    Zheng, Sean
    Chan, Fiona
    Roddick, Alistair
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1740 - 1740
  • [23] Response to Commentary for 'Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials'
    Mahmoud, Ahmed N.
    Gad, Mohamed M.
    Elgendy, Akram Y.
    Elgendy, Islam Y.
    Bavry, Anthony A.
    EUROPEAN HEART JOURNAL, 2019, 40 (34) : 2924 - 2925
  • [24] Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Liu, Shuangbo
    Eckstein, Janine
    Lam, Anna
    Cheema, Asim N.
    CURRENT VASCULAR PHARMACOLOGY, 2023, 21 (02) : 111 - 119
  • [25] Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis
    Stavrakis, Stavros
    Stoner, Julie A.
    Azar, Madona
    Wayangankar, Siddharth
    Thadani, Udho
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 341 (01): : 1 - 9
  • [26] Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials
    Kunutsor, S. K.
    Seidu, S.
    Khunti, K.
    DIABETIC MEDICINE, 2017, 34 (03) : 316 - 327
  • [28] Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials
    Barbarawi, Mahmoud
    Kheiri, Babikir
    Zayed, Yazan
    Gakhal, Inderdeep
    Al-Abdouh, Ahmad
    Barbarawi, Owais
    Rashdan, Laith
    Rizk, Fatima
    Bachuwa, Ghassan
    Alkotob, Mohammad Luay
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2019, 26 (04) : 283 - 291
  • [29] Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials
    Mahmoud Barbarawi
    Babikir Kheiri
    Yazan Zayed
    Inderdeep Gakhal
    Ahmad Al-Abdouh
    Owais Barbarawi
    Laith Rashdan
    Fatima Rizk
    Ghassan Bachuwa
    Mohammad Luay Alkotob
    High Blood Pressure & Cardiovascular Prevention, 2019, 26 : 283 - 291
  • [30] ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR AND ALL-CAUSE MORTALITY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Alrifai, A.
    Al Halabi, S.
    Rosenstein, R. S.
    CARDIOLOGY, 2015, 131 : 93 - 93